We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
Tilly's
TLYS
$114M
| $124K | ﹤0.01% |
13,778
+449
| +3% | +$5.1K |
|
|
WG
2752
DELISTED
Willbros Group
WG
| $123K | ﹤0.01% |
45,010
-147
| -0.3% | -$428 |
|
2753
Genie Energy
GNE
$370M
| $122K | ﹤0.01% |
16,792
+3,608
| +27% | +$21.1K |
|
2754
W&T Offshore
WTI
$525M
| $122K | ﹤0.01% |
44,145
+8,298
| +23% | +$23.8K |
|
|
PFNX
2755
DELISTED
Pfenex Inc.
PFNX
| $122K | ﹤0.01% |
21,031
+3,257
| +18% | +$24.5K |
|
2756
Lindblad Expeditions
LIND
$1.95B
| $119K | ﹤0.01% |
13,307
+2,361
| +22% | +$21.6K |
|
2757
Talphera
TLPH
$68M
| $119K | ﹤0.01% |
1,889
+311
| +20% | +$18.3K |
|
|
NAME
2758
DELISTED
Rightside Group, Ltd.
NAME
| $118K | ﹤0.01% |
+11,866
| New | +$103K |
|
2759
Marchex
MCHX
$78M
| $117K | ﹤0.01% |
43,016
+7,844
| +22% | +$21.1K |
|
2760
Gaia
GAIA
$46.6M
| $116K | ﹤0.01% |
+11,679
| New | +$102K |
|
2761
Lifeway Foods
LWAY
$480M
| $114K | ﹤0.01% |
+10,589
| New | +$116K |
|
|
FNBC
2762
DELISTED
First NBC Bank Holding Company
FNBC
| $113K | ﹤0.01% |
28,219
+6,377
| +29% | +$31.2K |
|
2763
Destination XL Group
DXLG
$32.9M
| $111K | ﹤0.01% |
38,928
-5,375
| -12% | -$16.6K |
|
2764
Nature's Sunshine
NATR
$362M
| $111K | ﹤0.01% |
11,076
-552
| -5% | -$6.43K |
|
|
ECYT
2765
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $111K | ﹤0.01% |
43,259
+553
| +1% | +$1.28K |
|
|
XRN
2766
Chiron Real Estate Inc
XRN
$535M
| $109K | ﹤0.01% |
2,398
+298
| +14% | +$12.9K |
|
2767
MidCap Financial Investment
MFIC
$801M
| $109K | ﹤0.01% |
5,550
+21
| +0.4% | +$389 |
|
2768
Vitamin Cottage Natural Grocers
NGVC
$760M
| $109K | ﹤0.01% |
10,518
+421
| +4% | +$5.02K |
|
|
CDTX
2769
DELISTED
Cidara Therapeutics
CDTX
| $108K | ﹤0.01% |
695
+31
| +5% | +$5.44K |
|
2770
Tidewater
TDW
$3.63B
| $108K | ﹤0.01% |
2,925
+523
| +22% | +$29.7K |
|
2771
MannKind Corp
MNKD
$1.19B
| $107K | ﹤0.01% |
72,108
+2,970
| +4% | +$7.8K |
|
|
HIVE
2772
DELISTED
Aerohive Networks
HIVE
| $107K | ﹤0.01% |
25,469
+1,127
| +5% | +$5.66K |
|
2773
Immunic
IMUX
$178M
| $103K | ﹤0.01% |
64
+3
| +5% | +$5.49K |
|
|
AGTC
2774
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $98K | ﹤0.01% |
14,235
+1,840
| +15% | +$14.4K |
|
|
NYRT
2775
DELISTED
New York REIT, Inc.
NYRT
| $98K | ﹤0.01% |
1,010
-21,404
| -95% | -$2.1M |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.